Red Light Holland - CEO, Todd Shapiro.
CEO, Todd Shapiro.
Source: LinkedIn.
  • Red Light Holland (TRIP) has released its updated plan to enter Oregon’s psilocybin market
  • Its Red Light. Set. Go! program will advise and fund Oregonian entrepreneurs interested in the space
  • The state’s Measure 109 will open psilocybin services to Oregonians 21 years and older without the need for medical diagnosis
  • Halo Collective and the company have agreed to dissolve Red Light Oregon
  • Red Light Holland is engaged in the production, growth and sale of magic truffles
  • Red Light Holland (TRIP) is unchanged trading at $0.075 per share

Red Light Holland (TRIP) has released its updated plan to enter Oregon’s psilocybin market.

The market will be created by adopting Measure 109, which will open psilocybin services to Oregonians 21 years and older without the need for medical diagnosis.

The company has created its Red Light. Set. Go! program to advise and fund Oregonians interested in entering the psilocybin space. It believes the program will enhance shareholder value and increase its Mycelium network.

Shunji Smith, a Japanese-American mushroom grower, teacher and small business owner from Eugene, Oregon, has joined Red Light under the program.

On December 31, 2022, the Oregon Health Authority will prescribe forms and regulations for Measure 109’s implementation.

“We noticed a big gap between Measure 109’s intentions and what we are seeing on the ground when it comes to promoting diversity and equity,” stated Todd Shapiro, Red Light Holland’s CEO. “The regulations are complex and entering the market requires initial capital that most individuals wishing to enter do not have access to.”

Dissolution of Red Light Oregon

Red Light is also announcing that Halo Collective and the company have agreed to dissolve Red Light Oregon.

Red Light Holland is engaged in the production, growth and sale of magic truffles.

Red Light Holland (TRIP) is unchanged trading at $0.075 per share as of 12:24 pm EST.

More From The Market Online

Psychedelic stock begins take-home LSD microdosing clinical trial

MindBio Therapeutics (CSE:MBIO) secures approvals for MB22001 – a form of LSD – microdosing use by patients in a controlled clinical trial.

Red Light Holland begins experimental research on psilocybin truffles

Red Light Holland has revealed that it has officially begun an experimental research project on its psilocybin truffles.
MindBio Therapeutics chief executive officer Justin Hanka.

Psychedelic stock clears hurdle to treating depression with LSD

Psychedelic stock MindBio (CSE:MBIO) is revealing positive top-line data from its pioneering microdosing clinical trial to treat depression.

Clearmind Medicine to begin alcohol use disorder clinical trial

Clearmind Medicine (CSE:CMND) has received approval to begin its phase I/IIa clinical trial for alcohol use disorder in Israel.